Evidence map›Paper›PMID 41028240›Full record

ArticleScientific reports2025

Discovery and molecular docking studies of nitrogen containing naphthyridine derivatives as potent HIV1 NNRTIs with anticancer potential.

Apisara Baicharoen, Pongsit Vijitphan, Suwicha Patnin, Nanthawan Reukngam, Panita Khlaychan, Mayuso Kuno, Apinya Chaivisuthangkura, Supanna Techasakul, Arthit Makarasen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Apisara BaicharoenDepartment of Chemistry, Laboratory of Organic Synthesis, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Pongsit VijitphanDepartment of Chemistry, Laboratory of Organic Synthesis, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Suwicha PatninDepartment of Chemistry, Laboratory of Organic Synthesis, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Nanthawan ReukngamDepartment of Chemistry, Laboratory of Organic Synthesis, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Panita KhlaychanDepartment of Chemistry, Laboratory of Organic Synthesis, Chulabhorn Research Institute, Bangkok, 10210, Thailand.
Mayuso KunoDepartment of Chemistry, Faculty of Science, Srinakharinwirot University, Bangkok, 10110, Thailand.
Apinya ChaivisuthangkuraDepartment of Chemistry, Faculty of Science, Srinakharinwirot University, Bangkok, 10110, Thailand.
Supanna TechasakulDepartment of Chemistry, Laboratory of Organic Synthesis, Chulabhorn Research Institute, Bangkok, 10210, Thailand. supanna@cri.or.th.
Arthit MakarasenDepartment of Chemistry, Laboratory of Organic Synthesis, Chulabhorn Research Institute, Bangkok, 10210, Thailand. arthit@cri.or.th.

Funding

Thailand Science Research and Innovation 36824/4274395Thailand Science Research and Innovation 49896/4759817
6 · The paper itself

Abstract

Fourteen novel 2,4-disubstituted-1,6- and 1,7-naphthyridine derivatives were developed to enhance HIV-1 RT inhibition through molecular hybridization of NNRTIs. The compounds were synthesized from nicotinate analogues via nucleophilic substitution and Buchwald-Hartwig reactions. Among them, 2-cyanopyridinyl-1,6-naphthyridines 16a, 16b, and 19a showed stronger activity than nevirapine (IC

Indexed as

Antineoplastic AgentsMolecular Docking SimulationNaphthyridinesNitrogenReverse Transcriptase InhibitorsDrug DiscoveryHeLa CellsHIV-1HIV Reverse TranscriptaseHL-60 CellsMolecular Dynamics SimulationStructure-Activity RelationshipAntineoplastic AgentsHIV Reverse TranscriptaseNaphthyridinesNitrogenReverse Transcriptase InhibitorsAnti-cancerCytotoxicHIV-1Molecular dockingNaphthyridineQuinoline

Identifiers

PMID41028240
PMCPMC12484987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.